

## T6. DHAP VS. IGEV AS MOBILIZATION TREATMENT IN PATIENTS WITH LYMPHOMAS- FUNDENI CLINICAL INSTITUTE EXPERIENCE

*Alexandra Mărculescu, Carmen Eleonora Călugaroiu, Alina Daniela Tănase, Zsofia Varady, Oana Gabriela Crăciun, Daniel Coriu, Anca Coliță, Luminița Dumitrache, Constantin Arion*

Bone Marrow Transplantation Center, Fundeni Clinical Institute, Bucharest, Romania

This work represents a 3 years retrospective study (January 2010 - December 2012) that wants to compare different mobilization regimens used in patients with different forms of malignant lymphomas.

### Material and Methods:

There have been accomplished 154 hematopoietic stem cells harvest for 146 patients with different forms of non-Hodgkin's lymphomas (LMNH) or different forms of Hodgkin's Disease (BH) with ages between 6 and 61 years in Clinical Institute Fundeni, in the period mentioned above.

In most cases a single apheresis procedure was enough, but 2 procedures were needed in 4 patients and 3 apheresis procedures were needed in a single patient.

DHAP regimen was used in 73 patients (40 females with ages between 12 and 56 years and 33 males with ages between 17 and 61 years); R-DHAP regimen was used in 4 females from this cohort.

IGEV regimen was used in 42 patients (21 females with ages between 21-53 years and 21 males with ages between 11-55 years); R-IGEV was used in 1 female and 1 male from this cohort.

HD-Etoposide regimen was used in 10 patients (5 females with ages between 19-58 years and 5 males with ages between 25-48 years).

Others regimens (R-ICE, HD-CFA, Ifosfamide-Vinorelbin-Dexametasone, Ifosfamide-Idarubicine-Etoposide, CHOP) were used as a mobilization treatment for a few patients in which neither DHAP nor IGEV regimen could be used for objective reasons.

Only G-CSF +/- Plerixafor alone (without chemotherapy) was used in 5 patients (2 females with ages 28 and 42 years and 3 males with ages 14-25 years).

### Results and Conclusions:

In (R)-IGEV cohort: 2,38% (1 patient) needed 5 days G-CSF; 11,90% (5 patients) needed 6 days G-CSF; 52,39% (22 patients) needed 7 days G-CSF; 16,67% (7 patients) needed 8 days G-CSF; 9,52% (4 patients) needed 9 days G-CSF; 4,76% (2 patients) needed 10 days G-CSF; 2,38% (1 patient) needed 12 days G-CSF. The smallest graft =  $1,65 \times 10^6$  CD34+cells/ body weight recipient and the largest graft =  $56,63 \times 10^6$  CD34+cells/b.w recipient in this cohort.

In (R)-DHAP cohort: 1,37% (1 patient) needed 5 days G-CSF; 8,22% (6 patients) needed 6 days G-CSF; 27,4% (20 patients) needed 7 days G-CSF; 32,88% (24 patients) needed 8 days G-CSF; 12,33% (9 patients) needed 9 days G-CSF; 12,33% (9 patients) needed 10 days G-CSF; 1,37% (1 patient) needed 11 days G-CSF; 4,1% (3 patients) needed 14 days G-CSF. The smallest graft =  $1,51 \times 10^6$  CD34+ cells/b.w recipient and the largest graft =  $31,28 \times 10^6$  / b.w. recipient in this cohort.

In conclusion, there is no significant differences between DHAP and IGEV regimen as mobilization treatment, although it seems that IGEV has a small advantage over DHAP.